These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35580925)

  • 1. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
    Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
    Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
    Mol Cell Proteomics; 2019 Jun; 18(6):1255-1268. PubMed ID: 31154438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble plasma HLA peptidome as a potential source for cancer biomarkers.
    Bassani-Sternberg M; Barnea E; Beer I; Avivi I; Katz T; Admon A
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18769-76. PubMed ID: 20974924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
    Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
    Mol Cell Proteomics; 2018 Nov; 17(11):2132-2145. PubMed ID: 30072578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery.
    Ritz D; Gloger A; Neri D; Fugmann T
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27862975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse.
    Rijensky NM; Blondheim Shraga NR; Barnea E; Peled N; Rosenbaum E; Popovtzer A; Stemmer SM; Livoff A; Shlapobersky M; Moskovits N; Perry D; Rubin E; Haviv I; Admon A
    Mol Cell Proteomics; 2020 Aug; 19(8):1360-1374. PubMed ID: 32451349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity.
    Amirghofran Z; Sheikhi AK; Kumar PV; Saberi Firouzi M
    J Cancer Res Clin Oncol; 2002 Aug; 128(8):443-8. PubMed ID: 12200601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera.
    Ritz D; Gloger A; Weide B; Garbe C; Neri D; Fugmann T
    Proteomics; 2016 May; 16(10):1570-80. PubMed ID: 26992070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
    Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
    Jarmalavicius S; Welte Y; Walden P
    J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
    Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
    J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.
    Yaciuk JC; Skaley M; Bardet W; Schafer F; Mojsilovic D; Cate S; Stewart CJ; McMurtrey C; Jackson KW; Buchli R; Olvera A; Cedeño S; Plana M; Mothe B; Brander C; West JT; Hildebrand WH
    J Virol; 2014 Nov; 88(22):12992-3004. PubMed ID: 25165114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.
    Ghosh M; Gauger M; Marcu A; Nelde A; Denk M; Schuster H; Rammensee HG; Stevanović S
    Mol Cell Proteomics; 2020 Mar; 19(3):432-443. PubMed ID: 31937595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions.
    Magyarosy E; Martin WJ; Chu EW; Martin SE
    Pathol Oncol Res; 1999; 5(1):32-5. PubMed ID: 10079375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma.
    de Beijer MTA; Bezstarosti K; Luijten R; Doff WAS; Boor PPC; Pieterman RFA; Bouzid R; Biesta PJ; Ijzermans JNM; Doukas M; de Man RA; Woltman AM; Demmers JAA; Buschow SI
    JHEP Rep; 2022 Nov; 4(11):100576. PubMed ID: 36185575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.
    Dutoit V; Herold-Mende C; Hilf N; Schoor O; Beckhove P; Bucher J; Dorsch K; Flohr S; Fritsche J; Lewandrowski P; Lohr J; Rammensee HG; Stevanovic S; Trautwein C; Vass V; Walter S; Walker PR; Weinschenk T; Singh-Jasuja H; Dietrich PY
    Brain; 2012 Apr; 135(Pt 4):1042-54. PubMed ID: 22418738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Untargeted mass spectrometry-based metabolomic profiling of pleural effusions: fatty acids as novel cancer biomarkers for malignant pleural effusions.
    Lam CW; Law CY
    J Proteome Res; 2014 Sep; 13(9):4040-6. PubMed ID: 25117182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.
    Ritz D; Sani E; Debiec H; Ronco P; Neri D; Fugmann T
    Proteomics; 2018 Jun; 18(12):e1700246. PubMed ID: 29314611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.